How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
Mehdi Yazdi the Art of API Method Development
Setting Comprehensive Specifications in API Manufacturing
When Does it Makes Sense for CDMOs to Collaborate?
PCI Synthesis’ Director of Analytical Services Dedicates Lab Expansion of Outsourcing Partner: Diace...
Why API manufacturing projects go over budget?
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...